Androgen receptor modulating compounds

Patent metadata

Field	Value
Publication number	US-9657003-B2
Application number	US-201514598973-A
Country	US
Kind code	B2
Filing date	Jan 16, 2015
Priority date	Oct 27, 2009
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

First claim

The invention claimed is:

1. A compound of formula (I):

wherein
R 1 is hydrogen, halogen, cyano, nitro or optionally substituted 5- or 6-membered heterocyclic ring;
R 2 is hydrogen, halogen, cyano, nitro, amino, C 1-7 alkyl, halo C 1-7 alkyl, hydroxy C 1-7 alkyl, thio C 1-7 alkyl or C 1-7 alkoxy;
R 3 is hydrogen, halogen or C 1-7 alkyl,
or R 2 and R 3 together with the carbon atoms to which they are attached form a optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring;
wherein at least two of R 1 , R 2 and R 3 are not hydrogen;
R 4 , R 4′ , R 5 , R 6 ; and R 7 are, independently, hydrogen, C 1-7 alkyl, halo C 1-7 alkyl or hydroxy C 1-7 alkyl;
ring atom E is C or N;
dashed line means an optional double bond;
A is a 5-12 membered heterocyclic ring;
B is a 5-membered heterocyclic ring wherein 1-3 of the members are heteroatoms selected from N, O and S;
R 8 is hydrogen, hydroxy, halogen, nitro, amino, cyano, oxo, C 1-7 alkyl, C 1-7 alkoxy, halo C 1-7 alkyl, hydroxy C 1-7 alkyl, cyano C 1-7 alkyl, amino C 1-7 alkyl, oxo C 1-7 alkyl, C 1-7 alkoxy C 1-7 alkyl, methylsulfonamido C 1-7 alkyl, oxiran C 1-7 alkyl, C 1-7 alkylamino, hydroxy C 1-7 alkylamino, C 1-7 alkoxy C 1-7 alkylamino, C 1-7 alkylamino C 1-7 alkyl, hydroxy C 1-7 alkylamino C 1-7 alkyl, hydroxyimino C 1-7 alkyl, halo C 1-7 alkylhydroxy C 1-7 alkyl, —C(O)R 10 , —OC(O)R 17 , —NH—C(O)R 18 or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring, each group optionally linked to A-ring via C 1-7 alkylene linker;
R 9 is hydrogen, halogen, C 1-7 alkyl, oxo, hydroxy C 1-7 alkyl, oxo C 1-7 alkyl or an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring, each group optionally linked to A-ring via C 1-7 alkylene linker;
R 10 is hydrogen, hydroxy, C 1-7 alkyl, hydroxy C 1-7 alkyl, halo C 1-7 alkyl, C 1-7 alkoxy, NR 11 R 12 , or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring;
R 11 is hydrogen, C 1-7 alkyl, hydroxy C 1-7 alkyl, amino C 1-7 alkyl, C 1-7 alkyl amino C 1-7 alkyl,
R 12 is hydrogen or C 1-7 alkyl;
R 13 and R 14 are, independently, hydrogen, C 1-7 alkyl, halogen, cyano or hydroxy C 1-7 alkyl;
R 15 and R 16 are, independently, hydrogen, oxo, thioxo, C 1-7 alkyl or cyano;
R 17 is C 1-7 alkyl, C 1-7 alkoxy, amino C 1-7 alkyl or C 1-7 alkylamino C 1-7 alkyl;
R 18 is C 1-7 alkyl, amino C 1-7 alkyl or C 1-7 alkylamino C 1-7 alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein B is

wherein Z is O, N, C═O or C═S;
X is C or N;
Y is C or N;
G is CH, C═O or C═S;
M is CH or 0;
R 13 and R 14 are, independently, hydrogen, C 1-7 alkyl, halogen, cyano or hydroxy C 1-7 alkyl;
dashed line means an optional double bond, and the asterisk denotes the point of attachment to the ring.

3. The compound according to claim 1 , wherein B is a group of formula (2′), (3′) or (4′)

wherein
R 13 and R 14 are, independently, hydrogen, C 1-7 alkyl, halogen, cyano or hydroxy C 1-7 alkyl; and
the asterisk denotes the point of attachment to the ring.

4. The compound according to claim 1 , wherein ring A is anyone of the following groups or tautomers thereof

5. The compound according to claim 4 , wherein
ring atom E is C,
R 1 is halogen, C 1-7 alkyl, cyano, nitro or halo C 1-7 alkyl,
R 2 is cyano, halogen or nitro,
R 3 is hydrogen, halogen or C 1-7 alkyl,
A is anyone of groups (5′), (6′), (7′), (8′), (12′), (20′), (21′), (27′) and (28′) or tautomers thereof,
B is a group of formula (2′), (3′) or (4′)

substituted by R 13 and R 14 , which are hydrogen,
R 4 (and R 4 ′ if applicable) is hydrogen or methyl,
R 5 is hydrogen or C 1-7 alkyl,
R 6 (if applicable) is hydrogen,
R 8 is hydrogen, C 1-7 alkyl, hydroxy C 1-7 alkyl, halogen, hydroxyimino C 1-7 alkyl, a 5 or 6 membered heterocyclic ring or —C(O)R 10 wherein R 10 is C 1-7 alkyl, and
R 9 is hydrogen, halogen or C 1-7 alkyl.

6. A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier.

7. A method for the treatment or prevention of androgen receptor dependent conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .

8. A method according to claim 7 , wherein the androgen receptor dependent condition is prostate cancer.

9. A method for the treatment or prevention of androgen receptor dependent conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I′)

wherein
R 1 is hydrogen, halogen, cyano, nitro or optionally substituted 5- or 6-membered heterocyclic ring;
R 2 is hydrogen, halogen, cyano, nitro, amino, C 1-7 alkyl, halo C 1-7 alkyl, hydroxy C 1-7 alkyl, thio C 1-7 alkyl or C 1-7 alkoxy;
R 3 is hydrogen, halogen or C 1-7 alkyl,
or R 2 and R 3 together with the carbon atoms to which they are attached form a optionally substituted 5- or 6-membered carbocyclic or heterocyclic ring;
wherein at least two of R 1 , R 2 and R 3 are not hydrogen;
R 4 , R 4′ , R 5 , R 6 ; and R 7 are, independently, hydrogen, C 1-7 alkyl, halo C 1-7 alkyl or hydroxy C 1-7 alkyl:
ring atom E is C or N;
is C or N;
dashed line means an optional double bond;
A is a 5-12 membered heterocyclic ring;
B is a 5-membered heterocylic ring wherein 1-3 of the members are heteroatoms selected from N, 0 and S;
R 8 is hydrogen, hydroxy, halogen, nitro, amino, cyano, oxo, C 1-7 alkyl, C 1-7 alkoxy, halo C 1-7 alkyl, hydroxy C 1-7 alkyl, cyano C 1-7 alkyl, amino C 1-7 alkyl, oxo C 1-7 alkyl, C 1-7 alkoxy C 1-7 , alkyl, methylsulfonamido C 1-7 alkyl, oxiran C 1-7 alkyl, C 1-7 alkylamino hydroxy C 1-7 alkylamino, C 1-7 alkoxy C 1-7 alkylamino, C 1-7 alkylamino C 1-7 alkyl, hydroxy C 1-7 alkylamino C 1-7 alkyl, hydroxyimino C 1-7 alkyl, halo C 1-7 alkylhydroxy C 1-7 alkyl, —C(O)R 10 , —OC(O)R 17 , —NH—C(O)R 18 or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring, each aroup optionally linked to A-ring via C 1-7 alkylene linker;
R 9 is hydrogen, halogen C 1-7 alkyl, oxo, or an optionally substituted 5 or 6 membered carbocyclic or heterocyclic ring, each group optionally linked to A-ring via C 1-7 alkylene linker;
R 10 is hydrogen, hydroxy, C 1-7 alkyl, hydroxy C 1-7 alkyl, halo C 1-7 , alkyl, C 1-7 alkoxy, NR 11 R 12 , or an optionally substituted 5-12 membered carbocyclic or heterocyclic ring;
R 11 is hydrogen, C 1-7 alkyl hydroxy C 1-7 alkyl, amino C 1-7 alkyl, C 1-7 alkyl amino C 1-7 alkyl,
R 12 is hydrogen or C 1-7 alkyl;
R 13 and R 14 are, independently

Assignees

• Orion Corp

Inventors

• Wohlfahrt Gerd
• Törmäkangas Olli
• Salo Harri
• Höglund Iisa
• Karjalainen Arja
• Koivikko Pia
• Holm Patrik
• Rasku Sirpa
• Vesalainen Anniina

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D405/12 Primary

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• C07D417/12

  linked by a chain containing hetero atoms as chain links · CPC title